• Join our free community, The Women’s Peptide Collective, click the Skool link to become a member and to connect, learn, and collaborate. https://www.skool.com/womens-peptide-collective-9663
• Go to https://thepeptique.com/ to get all your research peptides. As a loyal listener use the discount code POD15 to get 15% off the entire line of products.
• Have questions? Feel free to reach out to me: tarawest@westwellnessatx.com
• Want the free peptide guide? Email me tarawest@westwellnessatx.com and comment Guide and I'll shoot it right over!
• Follow me on instagram AND TikTOk @westwellnessatx
• Stay in touch add your email to the list ! https://form.jotform.com/25336471779006

In this episode of the West Wellness & Longevity Podcast, we break down one of the most common frustrations in GLP-1 research — the dreaded “stall.” Why do some individuals initially respond strongly to GLP-based peptides like tirzepatide, retatrutide, or semaglutide, only to see progress slow over time? We explore the research behind metabolic adaptation, receptor desensitization, appetite signaling, energy expenditure, and why the body may begin resisting continued weight loss. We also discuss emerging strategies being explored in the research space, including dose timing, pathway diversification, peptide stacking, and cycling approaches.

Takeaways:

• The stalling of weight loss while on GLP medications is multifactorial and varies significantly among individuals.
• Metabolic adaptation occurs as weight is lost, leading to a decrease in basal metabolic rate and energy expenditure.
• Inadequate protein intake can negatively impact satiety and lead to increased calorie consumption during weight loss efforts.
• Chronic stress and insufficient sleep can interfere with hormonal regulation, ultimately affecting the efficacy of GLP treatments.